[
  {
    "ts": null,
    "headline": "Moderna price target lowered to $33 from $40 at JPMorgan",
    "summary": "JPMorgan analyst Jessica Fye lowered the firm’s price target on Moderna (MRNA) to $33 from $40 and keeps an Underweight rating on the shares, primarily due to more conservative RSV and influenza estimates. The firm now models 2025 RSV sales of about $148M, versus a prior estimate of about $210M, and for FY25 it now models total revenue of $2.1B, versus consensus of $2.2B and just above the $2B guidance midpoint, the analyst tells investors. Published first on TheFly – the ultimate source for rea",
    "url": "https://finnhub.io/api/news?id=343165f19d589ed85c7d3986b2b920e5ecbf4b5becb90f32ed56ead88dd5bd6f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742650662,
      "headline": "Moderna price target lowered to $33 from $40 at JPMorgan",
      "id": 133327499,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "JPMorgan analyst Jessica Fye lowered the firm’s price target on Moderna (MRNA) to $33 from $40 and keeps an Underweight rating on the shares, primarily due to more conservative RSV and influenza estimates. The firm now models 2025 RSV sales of about $148M, versus a prior estimate of about $210M, and for FY25 it now models total revenue of $2.1B, versus consensus of $2.2B and just above the $2B guidance midpoint, the analyst tells investors. Published first on TheFly – the ultimate source for rea",
      "url": "https://finnhub.io/api/news?id=343165f19d589ed85c7d3986b2b920e5ecbf4b5becb90f32ed56ead88dd5bd6f"
    }
  },
  {
    "ts": null,
    "headline": "Buying These Dirt-Cheap Stocks Could Be a Brilliant Move",
    "summary": "Here's why they think Altimmune (NASDAQ: ALT), Moderna (NASDAQ: MRNA), and Pfizer (NYSE: PFE) are dirt cheap now, and why buying these value stocks could be a brilliant move.  David Jagielski (Altimmune): If you want to swing for the fences, one underrated GLP-1 weight loss drug company you'll want to consider investing in right now is Altimmune.  It's not the safest healthcare stock to own as there's no guarantee of how well its GLP-1 drug candidate, pemvidutide, will perform in late-stage trials, but its clinical results so far have been promising.",
    "url": "https://finnhub.io/api/news?id=145f8054377ae13b981df5c7c8e02898a0a450f33f294b1277a55883d9cda3ea",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742640240,
      "headline": "Buying These Dirt-Cheap Stocks Could Be a Brilliant Move",
      "id": 133325241,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Here's why they think Altimmune (NASDAQ: ALT), Moderna (NASDAQ: MRNA), and Pfizer (NYSE: PFE) are dirt cheap now, and why buying these value stocks could be a brilliant move.  David Jagielski (Altimmune): If you want to swing for the fences, one underrated GLP-1 weight loss drug company you'll want to consider investing in right now is Altimmune.  It's not the safest healthcare stock to own as there's no guarantee of how well its GLP-1 drug candidate, pemvidutide, will perform in late-stage trials, but its clinical results so far have been promising.",
      "url": "https://finnhub.io/api/news?id=145f8054377ae13b981df5c7c8e02898a0a450f33f294b1277a55883d9cda3ea"
    }
  },
  {
    "ts": null,
    "headline": "BUZZ Investing: Fed's Glimmer Of Hope Amid Market Corrections",
    "summary": "BUZZ Investing: Fed's Glimmer Of Hope Amid Market Corrections",
    "url": "https://finnhub.io/api/news?id=03408afa1952080181545aeb839354c59d0d91de887cdbdfbdbaa304f5c44835",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742613600,
      "headline": "BUZZ Investing: Fed's Glimmer Of Hope Amid Market Corrections",
      "id": 133312894,
      "image": "",
      "related": "MRNA",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=03408afa1952080181545aeb839354c59d0d91de887cdbdfbdbaa304f5c44835"
    }
  }
]